Medicinal plants against hepatitis C virus

被引:24
作者
Ashfaq, Usman A. [1 ]
Idrees, Sobia [1 ]
机构
[1] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan
关键词
Hepatitis C virus; Medicinal plants; Anti-hepatitis C virus drugs; GENOTYPES; INHIBITION; INTERFERON; INITIATION; QUERCETIN; RIBAVIRIN; EXTRACTS; SUBTYPES; PROTEIN; ENTRY;
D O I
10.3748/wjg.v20.i11.2941
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Hepatitis C virus (HCV) is a global health concern which is responsible for most of the liver diseases. Currently, there is no vaccine available for prevention of HCV infection due to the high degree of strain variation. The current standard of care is a combination of pegylated interferon a with ribavirin and boceprevir/telaprevir. This treatment was partially effective and had significant side effects. Hence, there is a need to develop new antiviral agents that interfere with different stages of the HCV life cycle. Recent advances in the understanding of both the cellular and molecular mechanisms of HCV replication have provided the basis for novel therapeutic strategies. Several hundred plant species and their phyto-constituents have been isolated for screening against HCV, and some have been shown to have great medicinal value in preventing and/or ameliorating viral diseases in pre-clinical and clinical trials. This review summarizes medicinal plants and their phytochemicals which inhibit different stages of HCV life cycle and discuss their potential use in HCV therapy. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:2941 / 2947
页数:7
相关论文
共 56 条
[1]
Aaronson N K, 1988, Prog Clin Biol Res, V269, P261
[2]
[Anonymous], VIROL MYCOL, DOI DOI 10.4172/2161-0517.1000112
[3]
REGENERATION OF THE MAGNOCELLULAR SYSTEM OF THE RHESUS-MONKEY FOLLOWING HYPOTHALAMIC-LESIONS [J].
ANTUNES, JL ;
CARMEL, PW ;
ZIMMERMAN, EA ;
FERIN, M .
ANNALS OF NEUROLOGY, 1979, 5 (05) :462-469
[4]
Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity [J].
Bachmetov, L. ;
Gal-Tanamy, M. ;
Shapira, A. ;
Vorobeychik, M. ;
Giterman-Galam, T. ;
Sathiyamoorthy, P. ;
Golan-Goldhirsh, A. ;
Benhar, I. ;
Tur-Kaspa, R. ;
Zemel, R. .
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) :E81-E88
[5]
BAGLIANI A, 1979, MINERVA CARDIOANGIOL, V27, P481
[6]
A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C: ViSER1 Results [J].
Benhamou, Yves ;
Afdhal, Nezam H. ;
Nelson, David R. ;
Shiffman, Mitchell L. ;
Halliman, Deanine G. ;
Heise, Jamie ;
Chun, Eric ;
Pockros, Paul J. .
HEPATOLOGY, 2009, 50 (03) :717-726
[7]
COMPLIANCE WITH ANTI-TUBERCULOUS THERAPY - A FIELD TRIAL OF A PILL-BOX WITH A CONCEALED ELECTRONIC RECORDING DEVICE [J].
CHEUNG, R ;
DICKINS, J ;
NICHOLSON, PW ;
THOMAS, ASC ;
SMITH, HH ;
LARSON, HE ;
DESHMUKH, AA ;
DOBBS, RJ ;
DOBBS, SM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (04) :401-407
[8]
The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry [J].
Ciesek, Sandra ;
von Hahn, Thomas ;
Colpitts, Che C. ;
Schang, Luis M. ;
Friesland, Martina ;
Steinmann, Joerg ;
Manns, Michael P. ;
Ott, Michael ;
Wedemeyer, Heiner ;
Meuleman, Philip ;
Pietschmann, Thomas ;
Steinmann, Eike .
HEPATOLOGY, 2011, 54 (06) :1947-1955
[9]
COEN DM, 1990, ANN NY ACAD SCI, V616, P224
[10]
AN EXPERIENCE OF WAR SURGERY AND WOUNDS PRESENTING AFTER 3 DAYS ON THE BORDER OF AFGHANISTAN [J].
COUPLAND, RM ;
HOWELL, PR .
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 1988, 19 (04) :259-262